Quidel to Hold Fourth Quarter and Full Year 2010 Results Conference Call on February 24, 2011

SAN DIEGO, CA--(Marketwire - February 4, 2011) - Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic tests, will release fourth quarter and full year 2010 financial results after market close on Thursday, February 24, 2011.

Following the release of results, Douglas Bryant, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and to answer questions. During the presentation, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.

To participate in the live call by telephone from the U.S., dial 866.510.0711, or from outside the U.S. dial 617.597.5379, and enter the pass code 71716499.

A live webcast of the call can be accessed at http://www.quidel.com, and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on February 24 by dialing 888-286-8010 from the U.S., or 617-801-6888 for international callers, and entering pass code 82016090.

About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of rapid diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the leading brand names QuickVue®, D³® Direct Detection and Thyretain™, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.

Contact Information:

Quidel Contact:
Quidel Corporation
John M. Radak
Chief Financial Officer
(858) 646-8032

Media and Investors Contact:
Ruben Argueta
Investor Relations Manager
(858) 646-8023